Citadel Advisors
PMCB icon

Citadel Advisors’s PharmaCyte Biotech PMCB Stock Holding History

Citadel Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.3K Sell
86,100
-74,100
-46% -$55.8K ﹤0.01% 12972
2026
Q1 		$107K Sell
160,200
-25,900
-14% -$19.8K ﹤0.01% 11958
2025
Q4 		$135K Buy
186,100
+175,500
+1,656% +$158K ﹤0.01% 11411
2025
Q3 		$10.3K Buy
+10,600
New +$10.6K ﹤0.01% 12561
2025
Q2 		– Sell
-13,700
Closed -$17.1K – 14502
2025
Q1 		$17.1K Buy
13,700
+4,400
+47% +$7.14K ﹤0.01% 13250
2024
Q4 		$14.4K Buy
+9,300
New +$16K ﹤0.01% 13405
2024
Q2 		– Sell
-5,400
Closed -$12.8K – 15121
2024
Q1 		$12.8K Sell
5,400
-2,800
-34% -$6.06K ﹤0.01% 13340
2023
Q4 		$17.7K Buy
8,200
+4,800
+141% +$10.4K ﹤0.01% 12728
2023
Q3 		$7.14K Sell
3,400
-1,000
-23% -$2.55K ﹤0.01% 13276
2023
Q2 		$12.6K Buy
4,400
+1,000
+29% +$3K ﹤0.01% 13072
2023
Q1 		$9.89K Sell
3,400
-31,600
-90% -$92.9K ﹤0.01% 13555
2022
Q4 		$102K Sell
35,000
-3,600
-9% -$10.3K ﹤0.01% 11186
2022
Q3 		$93K Buy
38,600
+21,800
+130% +$55.1K ﹤0.01% 11155
2022
Q2 		$38K Sell
16,800
-17,700
-51% -$38.7K ﹤0.01% 12095
2022
Q1 		$79K Buy
34,500
+21,800
+172% +$48.4K ﹤0.01% 12484
2021
Q4 		$32K Sell
12,700
-8,600
-40% -$23.7K ﹤0.01% 13456
2021
Q3 		$68K Buy
+21,300
New +$74.9K ﹤0.01% 13177

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Citadel Advisors's PMCB Position: Q2 2026 in Review

Citadel Advisors reduced its PharmaCyte Biotech (PMCB) stake by 21% in Q2 2026, selling an estimated $57.3K and leaving 283,381 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #11867.

Citadel Advisors first reported a position in PMCB in Q2 2022 and has held it in 11 quarters since. The position peaked at $239K in Q1 2026. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Citadel Advisors held 283,381 shares of PharmaCyte Biotech worth $218K as of Q2 2026.
  • Citadel Advisors sold 76,166 PharmaCyte Biotech shares in Q2 2026, an estimated $57.3K.
  • PharmaCyte Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11867 holding.
  • Citadel Advisors first reported a position in PharmaCyte Biotech in Q2 2022 and has held it in 11 quarters since.
  • Citadel Advisors's PharmaCyte Biotech position peaked at $239K in Q1 2026.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.